Session :
Multi-dimensional glucagon-like peptide-1 receptor agonists - Positioning their role in treatment of type 2 diabetes and cardiovascular disease
Session :
Multi-dimensional glucagon-like peptide-1 receptor agonists - Positioning their role in treatment of type 2 diabetes and cardiovascular disease
Session :
Multi-dimensional glucagon-like peptide-1 receptor agonists - Positioning their role in treatment of type 2 diabetes and cardiovascular disease
Speaker : L
Ryden
(Stockholm,SE), S
Verma
(Toronto,CA), M
Kosiborod
(Kansas,US)
ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.
Our mission: To reduce the burden of cardiovascular disease